Why Donate Blood on Testosterone Replacement Therapy?

Testosterone replacement therapy (TRT) stimulates the body to produce more red blood cells, sometimes pushing levels high enough to thicken the blood and raise the risk of clots. Donating blood pulls those excess red cells out of circulation, and it has become the go-to strategy for men on TRT who need to keep their hematocrit in a safe range. The practice is so common that TRT donors now make up a measurable share of the blood supply, though the science on whether donation alone is enough to manage the risk is less reassuring than many patients assume.

How Testosterone Drives Red Blood Cell Production

Testosterone does not just bump red blood cell counts up a little. In clinical studies, administering testosterone raised hemoglobin by about 7% and hematocrit by roughly 10%, and the mechanism involves more than one pathway working in the same direction. Testosterone stimulates the kidneys to produce more erythropoietin (EPO), the hormone that tells bone marrow to churn out red blood cells. At the same time, it suppresses hepcidin, a liver hormone that normally limits how much iron gets absorbed and released for use. With hepcidin turned down, more iron flows into the bone marrow, fueling even faster red blood cell production.¹ Animal studies confirmed the same picture: testosterone upregulated EPO gene expression in the kidneys while downregulating hepcidin in the liver.²

The net effect is that your body behaves as though it has recalibrated what it considers a “normal” red blood cell count. Instead of hovering at a typical hematocrit of 42–48%, many men on TRT drift above 50%, and some go considerably higher. That recalibration is the root of the problem, and the reason blood donation enters the conversation.

Why an Elevated Hematocrit Is Dangerous

A higher red blood cell count sounds like it should be a good thing, and in moderation it is. More red cells mean more oxygen delivery to tissues, which is part of why TRT can improve energy and exercise tolerance. But past a certain point, the blood becomes measurably thicker, and thicker blood is harder to push through vessels. It flows more slowly, it is more prone to forming clots, and those clots can lodge in critical places.

A large retrospective study found that men on testosterone therapy who developed polycythemia had roughly 35% higher odds of experiencing a major adverse cardiovascular event or venous thromboembolism compared to men on TRT whose hematocrit stayed normal.³ Population-level data also link testosterone-induced erythrocytosis to an increase in pulmonary embolism specifically, even when short-to-medium-term cardiovascular outcomes look otherwise acceptable.⁴ The traditional clinical response has been to stop TRT when hematocrit gets too high, but that forces men to choose between the benefits of testosterone and the safety of their cardiovascular system. Blood donation or therapeutic phlebotomy emerged as a way to keep both going.

Your Formulation Matters More Than You Might Think

Not every form of testosterone carries the same erythrocytosis risk. Injectable testosterone cypionate or enanthate, the most widely used formulations, produce the highest rates of elevated hematocrit by a wide margin. In one comparative study, about two-thirds of men on injectable testosterone developed a hematocrit above 50%, compared with roughly 13% on topical gels and about 35% on implanted pellets.⁵ The injectable group also hit that threshold faster, at around ten and a half months on average versus fourteen months for gels and over sixteen months for pellets.

A separate registry study comparing transdermal gel against long-acting intramuscular testosterone undecanoate found a similar pattern: the injection group had significantly more men crossing the 50% hematocrit line, and the gap held at higher thresholds of 52% and 54% as well.⁶

The reason comes down to pharmacokinetics. Injections create a spike of supraphysiological testosterone levels shortly after the shot, followed by a trough before the next one. Those peaks are what hammer the EPO system hardest. Gels deliver a steadier, lower dose throughout the day, keeping testosterone closer to normal physiological levels and producing less erythropoietic drive.⁷ If you are donating blood every eight weeks to manage your hematocrit, it is worth knowing that the formulation you are on may be the single biggest factor determining whether you need to donate at all.

Does Donating Blood Actually Keep You Safe?

Here is where the story gets uncomfortable. Many men on TRT, and many of their prescribing physicians, treat regular blood donation as a reliable safety valve. The logic seems sound: remove a unit of blood, hematocrit drops, problem solved. But at least one study found that repeat blood donation was not enough to maintain hematocrit below 54% in men on TRT.⁸ The researchers specifically flagged what they called a “misperception by patients and health care providers that donation has reduced or eliminated the risks of TRT-induced polycythemia.”

This does not mean donation is useless. Each unit of whole blood removes roughly 450–500 mL, and that predictably lowers hematocrit for a period. The problem is that if testosterone is continuously driving red cell production upward between donations, the effect may not last long enough to keep hematocrit in a safe window for the full eight weeks between eligible donations. Men who inject weekly and donate every 56 days may be spending most of their time with hematocrit levels higher than intended. The temporary dip after donation can create a false sense of security.

Why Blood Banks Instead of Hospitals

If phlebotomy is the treatment, you might wonder why men are showing up at the Red Cross instead of their doctor’s office. The answer is largely financial. Therapeutic phlebotomy performed at a hospital or infusion center is a medical procedure that comes with a bill, sometimes a substantial one depending on insurance coverage. A study analyzing the pattern directly concluded that individuals on TRT appear to be presenting to blood centers as volunteer donors to avoid the charges associated with therapeutic phlebotomy.⁹

Blood donation is free. You walk in, give blood, and walk out. The result is the same physiologically: a unit of blood leaves your body. But the context is different. Therapeutic phlebotomy is performed under medical supervision with the explicit goal of managing a disease state. Blood donation is a voluntary, altruistic act that produces a product intended for someone else. That distinction creates complications on both sides.

What Blood Banks See When TRT Donors Walk In

TRT donors are not invisible to blood collection organizations. Data from a large U.S. blood service found that TRT donors made up about 1.6% of the donor population but produced 2.2% of red blood cell units, reflecting their higher-than-average donation frequency. These donors had significantly higher hemoglobin levels (averaging 17.8 g/dL versus 15.6 in controls) and higher mean arterial blood pressure. They were more likely to be middle-aged, and about half had a BMI in the obese range.¹⁰

The donation frequency stood out especially: some TRT donors made as many as 29 donations over a two-year period, compared to a maximum of 12 in matched controls. That kind of intensity is a signal that these donors are not purely altruistic. They are managing a medical condition through the blood supply system, which raises questions about donor eligibility, recipient safety, and whether blood centers should screen for TRT use differently.

Eligibility Rules and the Regulatory Gray Area

Current donor eligibility regulations do not contain TRT-specific provisions. Blood centers handle these donors by assessing whether the intent is altruistic or therapeutic, applying standard eligibility criteria (hemoglobin/hematocrit must be within acceptable range, minimum time between donations, general health screening), and involving a medical director when the situation warrants.¹¹ In practice, this means many TRT donors sail through the screening process, since their hemoglobin is high enough to qualify and testosterone use is not a disqualifying medication at most centers.

There is a wrinkle with the plasma, though. FDA guidelines prevent the transfusion of plasma-based products from donors on TRT, because the plasma contains elevated testosterone concentrations.¹² The red blood cells from these donors can still be used, but the plasma is typically discarded or diverted. Research into pathogen reduction technology has shown it can mitigate the elevated testosterone in plasma, which could eventually change this policy, but for now it represents a resource loss for blood banks accepting TRT donors at high frequency.

The Iron Problem Nobody Mentions

Frequent blood donation depletes iron stores, and this is a particular concern for men who donate repeatedly to manage TRT-related erythrocytosis. Each unit of whole blood removes about 200–250 mg of iron. Testosterone itself already increases iron utilization by suppressing hepcidin and pulling more iron into red blood cell production.¹ Layering frequent blood donation on top of that creates a double drain.

Iron deficiency without anemia is a real phenomenon in frequent donors, and it comes with symptoms. A study of whole blood donors found that lower ferritin levels in men were associated with higher odds of fatigue, even when hemoglobin stayed normal.¹³ For a man on TRT who may have started therapy partly because of low energy, developing iron-deficiency fatigue from over-donating is an ironic outcome. His hemoglobin might look fine on a screening test because testosterone keeps pushing red cell production, masking the depleted iron stores underneath.

Ferritin testing is not part of standard blood donation screening. If you are donating every eight weeks to manage your hematocrit, ask your prescribing physician to check ferritin levels periodically. Some men end up needing iron supplementation alongside their donation schedule, which adds another layer of management to an already complicated regimen.

The Polycythemia Vera Hangover

Much of the clinical anxiety around elevated hematocrit on TRT traces back to a different disease entirely. Polycythemia vera is a bone marrow cancer that causes uncontrolled red blood cell production. It carries a well-documented risk of life-threatening thrombosis, and the standard treatment is phlebotomy to a hematocrit target below 45%. When TRT guidelines set hematocrit cutoffs for concern, they borrowed heavily from the polycythemia vera playbook, including the reflex to recommend phlebotomy.¹⁴

The problem is that testosterone-induced erythrocytosis and polycythemia vera are quite different conditions. In polycythemia vera, the bone marrow is driven by a mutation (usually JAK2 V617F), and the excess red cells are part of a broader myeloproliferative disorder that also affects platelets and white cells, all of which contribute to clot risk. In TRT-induced erythrocytosis, the extra red cells are a predictable pharmacological response to an external hormone, and the rest of the blood cell lines are not affected the same way. Whether the same hematocrit thresholds and the same phlebotomy targets make sense for both conditions is genuinely debated. Some researchers have questioned whether phlebotomy for TRT-induced erythrocytosis is even well justified, given the differences in underlying pathology.

Smarter Alternatives to Constant Donation

If donation is not a perfect solution, what else is on the table? The most straightforward option is switching formulations. As noted earlier, gels produce erythrocytosis at a fraction of the rate of injections. For men whose hematocrit climbs on injectable testosterone, switching to a transdermal gel may eliminate the problem without needing to donate at all.¹⁵ The trade-off is that gels can be less convenient (daily application, risk of transfer to partners or children through skin contact) and some men find they do not achieve the same testosterone levels.

Dose reduction is another approach. Lowering the amount of testosterone per injection or increasing the interval between injections can blunt the erythropoietic effect. However, at least one study of transgender men on biweekly cypionate injections found that simply spacing doses further apart did not reliably decrease hemoglobin or hematocrit.¹⁶ This suggests that for some people, the signal to make more red blood cells is already baked in at the hormonal level, and modest schedule changes are not enough to override it.

Some clinicians prescribe low-dose nasal testosterone (Natesto), which delivers very small pulses of testosterone multiple times a day, mimicking the body’s natural pulsatile secretion pattern. Others have explored medications like grapiprant or low-dose aspirin to address the clotting risk directly rather than trying to reduce hematocrit, though this is not yet standard practice.

Hydration and Timing Can Fool Your Blood Work

A practical detail that trips up many men on TRT: hematocrit is a ratio, not an absolute count. It measures the percentage of your blood volume that consists of red blood cells. If you are dehydrated when your blood is drawn, the plasma volume shrinks and the same number of red cells takes up a bigger percentage, giving you a falsely elevated hematocrit. Conversely, drinking a lot of water before a lab draw can temporarily dilute the reading downward.

This matters because clinical decisions about whether to donate, reduce your dose, or stop TRT are often made based on a single hematocrit reading. If you had coffee and no water the morning of your blood draw, your hematocrit may read two or three percentage points higher than your true steady-state value. Some men end up donating blood they did not need to lose, while others get a reassuringly normal reading after hydrating heavily and miss the fact that their baseline is actually elevated. The best practice is to hydrate normally (not excessively, not deficiently) before any lab draw, and to flag for your doctor if the conditions were unusual.

Timing relative to your injection also matters. If you inject weekly and get your blood drawn the day after an injection, when testosterone and its downstream effects are peaking, your hematocrit will read higher than if you drew blood five or six days later in the trough. Consistent timing across lab draws gives you and your doctor a clearer trend to work with.

What TRT Donors Should Actually Monitor

If you are on TRT and donating blood regularly, the minimum set of labs to track goes beyond just hematocrit. Ferritin is essential, because as described earlier, frequent donation in the setting of suppressed hepcidin can quietly drain your iron stores while your hemoglobin stays deceptively normal. A complete blood count gives you not just hematocrit but also red cell indices that can hint at early iron deficiency before symptoms appear. And a reticulocyte count, which measures immature red blood cells, can tell you how aggressively your marrow is producing new cells between donations.

Your prescriber should also be checking hematocrit at regular intervals regardless of whether you are donating. Guidelines from multiple endocrine societies recommend checking at three to six months after starting TRT and periodically thereafter, with a hematocrit above 54% generally flagged as requiring intervention. The 54% threshold is not universally agreed upon, and some clinicians act earlier at 50% or 52%, but it represents the point at which most guidelines say something needs to change, whether that means donating, switching formulations, lowering the dose, or temporarily stopping treatment.